Az összefoglaló blokkok és a teljes cikk szövege angolul van, szerkesztőségi egység miatt. A cím, a leírás és ez a bevezető doboz a választott nyelven jelenik meg.

FDA Peptide Compounding: The Ban, the 12 Under Review, and What It Means

Breaking: April 15, 2026 — 12 Peptides Removed from the Ban for Expert Review

On April 15, 2026, the FDA announced it would remove 12 peptides from Category 2 — the "significant safety concerns" list that banned them from compounding pharmacies since late 2024 — and send them to the Pharmacy Compounding Advisory Committee (PCAC) for deeper expert review.

This is not approval. It is the FDA stepping back to let a specialist panel weigh clinical need and safety data before making a final call. But it is a meaningful softening — these peptides are no longer categorically dismissed.

The 12 peptides under PCAC review:

Public comments are open through July 22, 2026 (FDA docket FDA-2025-N-6895).

The 2024 Ban: What Happened

In late 2024, the FDA finalized its decision to add a significant number of peptide compounds to the Category 2 Bulk Drug Substances list — effectively prohibiting licensed US compounding pharmacies from producing or dispensing them. This is the most significant regulatory shift in the US peptide research and wellness space in years.

What "Category 2" Means

US compounding law allows pharmacies to compound drugs from bulk drug substances — but only from substances on an approved list (Category 1). Category 2 is where the FDA places substances it has evaluated and determined lack a clinical need that would justify compounding, or where there are safety or regulatory concerns.

Being placed on Category 2 does not make a peptide illegal to possess as an individual, but it removes the primary legitimate domestic supply channel — licensed compounding pharmacies that operate under state board and federal oversight.

Peptides Affected by the Ban

The FDA's 2024 action included, but is not limited to:

Note: This list reflects publicly available information as of early 2026. Confirm current status with regulatory sources, as legal challenges may affect enforcement.

What Changed in Practice

Before the ban: Patients in the US could obtain prescriptions for many of these peptides from licensed compounding pharmacies that sourced pharmaceutical-grade bulk material.

After the ban: That supply chain is no longer available through licensed US compounders. Researchers and patients seeking these compounds now face:

• Research-grade gray-market sources with variable quality and no pharmacy oversight.
• International sources with their own regulatory complexities.
• Clinical trial access for compounds with active trials (limited by eligibility).

Legal Challenges and Ongoing Uncertainty

The ban has been met with active legal challenges from compounding pharmacy associations and patient advocacy groups, arguing the FDA's clinical-need determinations were insufficiently supported. As of mid-2026:

• Some challenges are unresolved in federal courts.
• Enforcement may vary by compound and supply chain context.
• The regulatory landscape is not fully settled.

Researchers should verify current status for any specific compound rather than treating the 2024 list as final.

What This Means for Evidence and Access

The compounding ban has a secondary effect on evidence generation: if licensed US facilities cannot produce these compounds, running US-based clinical trials becomes harder, reinforcing the existing evidence gap for many of these peptides. This is a systemic concern for the field, not just a consumer-access question.

Key Distinctions: Banned from Compounding ≠ Illegal

• Banned from compounding: Compounding pharmacies cannot make or dispense the compound.
• Research-grade supply: Still exists through research chemical suppliers — separate regulatory category with its own risks (no pharmacy oversight, variable purity).
• Individual possession: Generally not criminalized in the US for research peptides, though this varies by compound (some have DEA scheduling implications independently).
• FDA-approved versions: Where an FDA-approved drug exists (e.g., Vyleesi for PT-141, Egrifta for tesamorelin), those remain available via standard prescription channels.

Bottom Line

The 2024 FDA compounding ban materially changed the US peptide access landscape. Understanding what changed — and what it did not change — is essential context for any researcher following these compounds. Legal uncertainty remains; the landscape will continue to evolve.

Educational content only. Not medical advice. Verify current regulatory status in your jurisdiction.